BofA raised the firm’s price target on Arrowhead (ARWR) to $62 from $42 and keeps a Buy rating on the shares. Following fiscal Q4 results, the firm increased its price target to reflect clinical execution of Arrowhead’s obesity and partnered neuromuscular programs ahead of initial Phase 1/2 readouts, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR: